Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension
- 19 July 2005
- journal article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 46 (4) , 697-704
- https://doi.org/10.1016/j.jacc.2005.01.066
Abstract
No abstract availableKeywords
Funding Information
- Actelion Pharmaceuticals
- National Institutes of Health
- National Center for Research Resources
This publication has 24 references indexed in Scilit:
- Survival with first-line bosentan in patients with primary pulmonary hypertensionEuropean Respiratory Journal, 2005
- Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2European Respiratory Journal, 2004
- Outcomes in Children With Idiopathic Pulmonary Arterial HypertensionCirculation, 2004
- Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentanThe American Journal of Cardiology, 2004
- Inhaled IloprostDrugs, 2004
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- MEDICAL THERAPY OF PULMONARY HYPERTENSION: The ProstacyclinsClinics in Chest Medicine, 2001
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- Primary pulmonary hypertension in children: Clinical characterization and survivalJournal of the American College of Cardiology, 1995
- Expression of Endothelin-1 in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1993